INTRODUCTION: @entity40934 -like @entity784 (SPTL-AB) and @entity784 ( @entity784 ) are rare @entity784 with varying clinical courses. There is no standard treatment, although chemotherapy and hematopoietic stem cell transplantation are commonly used. We describe results using @entity35406 for @entity1 and adults with these disorders. METHODS: We identified 15 @entity1 (12 adults, 3 @entity1 ) who were treated with @entity35406 between 2000 and 2010 from the Memorial Sloan-Kettering @entity5 Center @entity706 database, the @entity5 Center Registry, and the National @entity5 Institute (NCI) @entity706 database. There were 8 females and 7 males, with a median age of 45 years (range, 3 years to 85 years). All @entity1 had stage IV disease. Two of 15 and 4 of 15 @entity1 had documented @entity784 and SPTL-AB, respectively; others were presumed to have SPTL-AB. @entity35406 was administered at flat doses corresponding to 91 to 339 mg/m(2)/d. Two of 15 @entity1 received concurrent denileukin diftitox. Two @entity1 received @entity35406 as maintenance therapy and were not evaluable for response. RESULTS: Among those treated with @entity35406 alone, the overall response rate (ORR) was 82% (6/11 complete response [CR], 3/11 partial response [PR]). One of the 2 @entity1 treated with concomitant denileukin diftitox responded for an ORR of 10/13 (77%), including 54% CR and 23% PR. Median progression-free survival was 38.4 months; median duration of response was 26.3 months. Six @entity1 developed @entity1375 and 9 developed @entity407 ; one @entity1 developed dose-limiting @entity2298 . One pediatric @entity1 developed @entity1723 . CONCLUSIONS: In this retrospective series, @entity35406 showed a high response rate in SPTL-AB and @entity784 . It was generally well-tolerated with durable responses; therefore, @entity35406 represents a promising therapy for @entity1 and adults with these disorders.

@entity35406 is active against @entity40934 -like XXXX in adult and pediatric populations.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient'] @entity1375 :: ('MESH:D007037', 'Disease') :: ['hypothyroidism'] @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia'] @entity2298 :: ('MESH:D015228', 'Disease') :: ['hypertriglyceridemia'] @entity35406 :: ('MESH:C095105', 'Chemical') :: ['bexarotene', 'Bexarotene'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'pediatric lymphoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Stanford Cancer', 'Cancer'] @entity784 :: ('MESH:D016399', 'Disease') :: ['CGD-TCL', 'cutaneous gamma/delta T-cell lymphoma', 'T-cell lymphomas', 'T-cell lymphoma'] @entity40934 :: ('MESH:C537503', 'Disease') :: ['Subcutaneous panniculitis'] @entity1723 :: ('MESH:D003922', 'Disease') :: ['insulin-dependent diabetes mellitus']
@entity784 :: (MESH:D016399,Disease) :: ['T-cell lymphoma']
